Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor

Neurology

Volumn 53, Issue 8, 1999, Pages 1719-1723

  Keime Guibert, F ^a   Graus, Francesc ^c   Broet P ^b   Rene R ^d   Molinuevo, J L ^c   Ascaso, C ^d   Delattre, J Y ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c HOSPITAL CLÍNIC   (Spain)

^d NONE

Author keywords

Anti Hu associated encephalomyelitis; Cancer; Paraneoplastic; Small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; AUTOANTIBODY; IMMUNOLOGIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; DISEASE ASSOCIATION; DISEASE COURSE; DRUG RESPONSE; ENCEPHALOMYELITIS; FEMALE; HUMAN; IMMUNOTHERAPY; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 0033544350     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.8.1719     Document Type: Article

References (25)

1. Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy: a clinical study of 71 patients. Medicine 1992;71: 59-72.
2. Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profile of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 1998;50:652-657.
3. Graus F, Vega F, Delattre JY, et al. Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal antibodies. Neurology 1992;42:536-540.
4. Uchuya M, Graus F, Vega F, Reñé R, Delattre JY. Intravenous immunoglobulin treatment in paraneoplastic neurologic syndromes with antineuronal antibodies. J Neurol Neurosurg Psychiatry 1996;60:388-392.
5. Digre KB. Opsoclonus in adults: report of three cases and review of the literature. Arch Neurol 1986;43:1165-1175.
6. Chalk CH, Murray NMF, Newsom-Davis J, O'Neill JH, Spiro SG. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 1990;40:1552-1556.
7. Graus F, Delattre JY. Immune modulation of paraneoplastic neurological disorders. Clin Neurol Neurosurg 1993;97:112-116.
8. Darnell RB, De Angelis LM. Regression of small cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 1993;341:21-22.
9. Graus F, Dalmau J, Reñé R, et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 1997; 15:2866-2872.
10. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980;65:25-32.
11. Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley, 1989.
12. France LA, Lewis JA, Kay R. The analysis of failure time data in crossover studies. Stat Med 1991;10:1099-1113.
13. Kalbfleish JD, Prentice RL. The statistical analysis of failure time data. New York: Wiley, 1980.
14. Grisold W, Drlicek M, Liszka-Setinek U, Wondrusch. Antitumor therapy in paraneoplastic neurologic disease. Clin Neurol Neurosurg 1995;97:106-111.
15. Byrne T, Mason WP, Posner JB, Dalmau J. Spontaneous neurological improvement in anti-Hu associated encephalomyelitis. J Neurol Neurosurg Psychiatry 1997;62:276-278.
16. Dropcho EJ. Autoimmune central nervous system paraneoplastic disorders: mechanisms, diagnosis and therapeutic options. Ann Neurol 1995;37(suppl 1):S102-S113
17. Darnell RB. Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. Proc Natl Acad Sci USA 1996;93:4529-4536.
18. Oh SJ, Dropcho EJ, Claussen GC. Anti-Hu-associated paraneoplastic sensory neuronopathy responding to early aggressive immunotherapy: report of two cases and review of literature. Muscle Nerve 1997;20:1576-1582.
19. Cher LM, Hochberg FH, Teruya J, et al. Therapy for paraneoplastic neurologic syndromes in six patients with protein A column immunoadsorption. Cancer 1995;75:1678-1683.
20. Altman AJ, Baehner RL. Favorable prognosis for survival in children with coincident opso-myoclonus and neuroblastoma. Cancer 1976;37:846-852.
21. Abrams J, Doyle LA, Aisner J. Staging, prognostic factors, and special considerations in small cell lung cancer. Semin Oncol 1988;15:261-277.
22. Santoro A, Parra HS, Bidoli P, et al. A summary of the Milan experience with multimodality therapies in patients with small cell lung cancer: attempts to improve long-term outcome. Semin Oncol 1995;22:9-14.
23. Sandler AB. Current management of small cell lung carcinoma. Semin Oncol 1997;24:463-476.
24. Chartrand-Lefebvre C, Howarth N, Grenier P, Keime F, Orcel B, Beigelman C. Association of small cell lung cancer and anti-Hu paraneoplastic syndrome: radiographic and CT findings. AJR 1998;170:1513-1517.
25. Shepherd FA, Ginsberg RJ, Haddad R, et al. Importance of clinical staging in limited small-cell lung cancer: a valuable system to separate prognostic subgroups. J Clin Oncol 1993; 11:1592-1597.